Clinical Trials Logo

Filter by:
NCT ID: NCT06197672 Recruiting - Clinical trials for Acute Myeloid Leukemia

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

Start date: March 19, 2024
Phase: Phase 1
Study type: Interventional

This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory AML. the study will evaluate safety in this patient population and also the presence of efficacy signal described by elimination of residual disease to qualify patients for stem cell transplant.

NCT ID: NCT06197308 Recruiting - Clinical trials for Primary Sclerosing Cholangitis

Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC

Start date: March 1, 2024
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial will evaluate the initial safety and feasibility of microbiota transplant therapy (MTT) inpatients with primary sclerosing cholangitis (PSC). This trial will inform development of future trials in treatment of PSC.

NCT ID: NCT06197282 Completed - COVID-19 Clinical Trials

Impact of COVID-19 on Surgical Outcomes

Start date: May 5, 2020
Phase:
Study type: Observational

Following the introduction of the COVID-19 vaccination, elective surgeries have resumed, allowing for greater insight into the postoperative period and outcomes aims on-going COVID-19 infections. This study aimed to evaluate risk factors of postoperative morbidity and mortality in patients who had surgery within one year of testing positive for COVID-19.

NCT ID: NCT06197243 Recruiting - Anxiety Clinical Trials

Augmenting Benzodiazepine Receptor Agonist Deprescribing With Acupuncture and Yoga Among Older Adults

Start date: December 14, 2023
Phase: N/A
Study type: Interventional

The main purpose of this 12-week study is to see if a new combination of treatments can help older adults reduce benzodiazepine or related medication use. The treatment combination consists of 1) medical provider visits to gradually reduce the medication dose over 12 weeks, 2) acupuncture treatments, and 3) private yoga classes. Participants will be offered weekly visits for 12 weeks to receive combined treatments. Participants will be provided surveys before, during, and after the study to learn about their experience of the treatments. At the end of the study, participants will be invited to participate in a focus group to learn about their experience in the study.

NCT ID: NCT06196879 Recruiting - Severe Asthma Clinical Trials

A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)

Start date: February 27, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.

NCT ID: NCT06196489 Recruiting - E Cigarette Use Clinical Trials

Adapting an Intervention for Vaping in Young Veterans

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

The objective of this proposal is to adapt an evidence-based combustible tobacco counseling intervention following an evidence-based process to include e-cigarette use and update its components for emerging adults (EA). 1. Examine factors related to e-cigarette use, barriers to cessation, and facilitators of use of cessation services among an EA population. 2. Beta-test an initial version of the intervention, delivered via video telehealth and telephone, to examine usability and acceptability.

NCT ID: NCT06196203 Recruiting - Clinical trials for Higher-risk Myelodysplastic Syndromes

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Start date: February 7, 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of AK117 or placebo, combined with azacitidine in patients with newly diagnosed higher-risk myelodysplastic syndromes (HR-MDS).

NCT ID: NCT06196008 Recruiting - Lung Carcinoma Clinical Trials

Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers

Start date: December 5, 2023
Phase: N/A
Study type: Interventional

This clinical trial compares telephone-based physical activity coaching to self monitored physical activity for improving physical function in older adults who are undergoing surgery for lung cancer and their caregivers. Lung cancer surgery in older adults is associated with functional declines and unique challenges. Performing physical activity around the time of surgery has been shown to improve functional outcomes in patients and exercise programs delivered via telehealth may improve access and convenience for patients and minimize participant burden. Telephone-based physical activity coaching may improve physical functioning for older adults with lung cancer who are undergoing surgery.

NCT ID: NCT06195982 Enrolling by invitation - Clinical trials for Heart Failure With Reduced Ejection Fraction

Ketones in Heart Failure With Reduced Ejection Fraction

HFrEF
Start date: March 6, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to understand the effects of a ketone drink on exercise capacity and other cardiovascular parameters in patients with heart failure. In heart failure, patients are limited in their ability to do all the things they want to do, and exercise as much as they would like, due to becoming tired and short of breath early. There may be several reasons why these symptoms occur. This study is assessing whether the ketone drink can improve these symptoms. This drink has been given status by Food and Drug Administration as "generally regarded as safe". The use of DeltaG in this study is experimental. DeltaG has not been approved by the Food and Drug Administration (FDA) for the use being evaluated in this study.

NCT ID: NCT06195943 Recruiting - Exercise Clinical Trials

Feasibility, Safety and Acceptability of a Mobile Health Delivered Exercise Training Program in Patients With Nonalcoholic Steatohepatitis

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

This study will be a pilot study to evaluate the feasibility, safety and acceptability of Exercise and Liver FITness (EL-FIT), a mHealth exercise training program previously validated in patients with cirrhosis in patients with nonalcoholic steatohepatitis.